biomodal, today announced at the AGBT 2026 General Meeting that biomodal’s duet multiomic solutions are compatible with Element Biosciences AVITI24™ 5D multiomics and AVITI™ sequencing instruments.
Dr. Sophie Kirschner, Associate Director, Translational Medicine, Early Oncology at AstraZeneca will present data using biomodal’s 6-base multiomics sequencing solution, duet evoC.
Distinguishing 5mC and 5hmC, enabled through duet evoC and the 6-base genome, delivered an AUC of 0.95 for stage I colorectal cancer from liquid biopsy, improving the earlier detection of stage I colorectal cancer from cfDNA samples!
biomodal has debuted in the top 10 of The Sunday Times Top 100 Tech Companies 2026.
biomodal announced it has filed a lawsuit against Watchmaker Genomics (“Watchmaker”) in the US District Court for the District of Colorado.
Explore the importance of epigenetics and how it shapes health, disease, and precision medicine through gene regulation, and DNA methylation.
This study demonstrates the value of moving beyond legacy epigenetic sequencing technologies that provide a modC readout.
Patterns of 5hmC and 5hmC provide insight into tissue-specific gene expression with the ability to better distinguish high and low expressed genes than 5mC or 5modC data.
This poster demonstrates compatibility of duet evoC with formalin-damaged DNA including clinical FFPE samples.
Using modality XPLR, we reveal variation in 5mC and 5hmC levels across tissues, with a pronounced increase in 5hmC in cerebellum and concomitant decrease in 5mC.